What's in Xiamen Amoytop Biotech Co., Ltd.'s pipeline?

Xiamen Amoytop Biotech Co., Ltd. has 12 drugs in our index: 1 marketed, 0 filed, 4 in Phase 3, 3 in Phase 2, 4 in Phase 1.

Which companies overlap with Xiamen Amoytop Biotech Co., Ltd.'s portfolio?

Top competitors by shared drug class: Adocia, Asan Medical Center, Ascendis Pharma A/S, Australasian Gastro-Intestinal Trials Group, Bayer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/xiamen-amoytop-biotech-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Xiamen Amoytop Biotech Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Xiamen Amoytop Biotech Co., Ltd. pipeline: 1 marketed, 0 filed, 4 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 4 Phase 3 3 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
rhG-CSF+rhGM-CSF group	rhG-CSF+rhGM-CSF group	marketed	Hematopoietic growth factor combination	G-CSF receptor; GM-CSF receptor	Oncology; Hematology
Ypeginterferon alfa-2b	Ypeginterferon alfa-2b	phase 3	Interferon	Interferon receptor	Oncology, Infectious Diseases
YPEG-rhG-CSF	YPEG-rhG-CSF	phase 3	G-CSF agonist	G-CSF receptor	Oncology
rhG-CSF/PEG-rhG-CSF	rhG-CSF/PEG-rhG-CSF	phase 3	Growth factor	G-CSF receptor	Oncology
Inpegsomatropin Injection	Inpegsomatropin Injection	phase 3	Growth hormone analog	Growth hormone receptor (GHR)	Endocrinology

Therapeutic area mix

Oncology · 2
Endocrinology · 1
Oncology, Infectious Diseases · 1
Oncology; Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Adocia · 1 shared drug class
Asan Medical Center · 1 shared drug class
Ascendis Pharma A/S · 1 shared drug class
Australasian Gastro-Intestinal Trials Group · 1 shared drug class
Bayer · 1 shared drug class
Biogen · 1 shared drug class
Case Comprehensive Cancer Center · 1 shared drug class
Active Biotech AB · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Xiamen Amoytop Biotech Co., Ltd.:

Cite this brief

Drug Landscape (2026). Xiamen Amoytop Biotech Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/xiamen-amoytop-biotech-co-ltd. Accessed 2026-05-16.